Infographics
CardioVascular Prevention 4 + 2 = CV Prevention 4 Steps of Risk Stratification Qualitative Risk ApproximationIdentify major risk factors, initiate counseling, and education. Quantitative Risk EstimationUse a validated model, such as Pooled Cohort Equations in the United States. Risk Enhancing FactorsFor individuals with intermediate risk, assess additional poorly represented factors.…
ABCDEF’s of CVD Prevention This infographic provides an easy-to-remember mnemonic for cardiovascular disease prevention, covering the major elements: A (Assess the Risk & AC): Use tools like the pooled cohort equation to assess the 10-year risk and consider additional factors like CAC score, aspirin, and anticoagulation when appropriate. B (BMI…
Causes of Hypertriglyceridemia This infographic provides an overview of hypertriglyceridemia, the most common dyslipidemia affecting about 30% of the population. Hypertriglyceridemia often begins at levels of ≥150 mg/dl, though even high-normal values (100-140 mg/dl) may carry increased cardiovascular risk. Key causes are summarized with the mnemonic "High Lipids Cause Morbidity":…
Family History of Premature ASCVD: FAQs in CVD Prevention Clinic A family history of premature ASCVD (atherosclerotic cardiovascular disease) includes events such as heart attack, stroke, or other cardiovascular incidents in first-degree relatives under age 55 for men or under 65 for women. This history is a risk-enhancing factor, especially…
Lp(a) and Cardiovascular Risk This infographic provides an overview of Lp(a) or lipoprotein(a), a genetically determined LDL-like particle associated with cardiovascular risk. The content covers biochemistry, genetics, manifestations, pathophysiology, therapeutic options, future directions in treatment, and clinical guidelines for measuring and evaluating Lp(a) levels. Produced by: Dr. Christian Faaborg AndersenEditors:…
Non-Statin Lipid Lowering Agents This table provides an overview of various non-statin lipid-lowering agents, summarizing their mechanisms, lipid-lowering efficacy, impact on major adverse cardiovascular events (MACE), advantages, and disadvantages. Drug Classes Covered: Bempedoic Acid Inclisiran PCSK9 Inhibitors (Evolocumab, Alirocumab) Ezetimibe Bile Acid Sequestrants Niacin Fibrates Omega-3 Fatty Acids (EPA) Each…
LDL-C vs Apo-B This infographic reveals how LDL-C (low-density lipoprotein cholesterol) concentrations may not tell the full story about cardiovascular risk. It explains that LDL particles can vary in size and density, with smaller, denser particles linked to increased risk of atherosclerosis. These misleading LDL-C values can underestimate cardiovascular risk…